Natera

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Natera 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About NTRA

Natera, Inc. is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT). 

CEO
Stephen Leonard Chapman
CEOStephen Leonard Chapman
Employees
6,140
Employees6,140
Headquarters
Austin, Texas
HeadquartersAustin, Texas
Founded
2003
Founded2003
Employees
6,140
Employees6,140

NTRA Key Statistics

Market cap
32.80B
Market cap32.80B
Price-Earnings ratio
-139.40
Price-Earnings ratio-139.40
Dividend yield
Dividend yield
Average volume
1.33M
Average volume1.33M
High today
$234.14
High today$234.14
Low today
$219.53
Low today$219.53
Open price
$231.52
Open price$231.52
Volume
1.58M
Volume1.58M
52 Week high
$256.36
52 Week high$256.36
52 Week low
$131.81
52 Week low$131.81

Stock Snapshot

The current Natera(NTRA) stock price is $228.80, with a market capitalization of 32.8B. The stock trades at a price-to-earnings (P/E) ratio of -139.40.

On 2026-06-23, Natera(NTRA) stock traded between a low of $219.53 and a high of $234.14. Shares are currently priced at $228.80, which is +4.2% above the low and -2.3% below the high.

Natera(NTRA) shares are trading with a volume of 1.58M, against a daily average of 1.33M.

In the last year, Natera(NTRA) shares hit a 52-week high of $256.36 and a 52-week low of $131.81.

In the last year, Natera(NTRA) shares hit a 52-week high of $256.36 and a 52-week low of $131.81.

NTRA News

Investing.com 5h
Natera co-founder Sheena Jonathan sells $329,809 in company stock - Investing.com

...

Natera co-founder Sheena Jonathan sells $329,809 in company stock - Investing.com
TipRanks 14h
NCCN guidelines may be meaningful catalyst for Natera, says Leerink

Leerink analyst Puneet Souda tells investors in a research note that the latest NCCN bladder cancer guidelines newly support MRD testing in muscle-invasive blad...

Simply Wall St 3d
Natera Stock Could Be 11.3% Undervalued After Prospera Transplant Data

Natera (NTRA) is back in focus after new transplant data at the 2026 American Transplant Congress linked its Prospera test to future adverse outcomes even when...

Natera Stock Could Be 11.3% Undervalued After Prospera Transplant Data

Analyst ratings

87%

of 23 ratings
Buy
87%
Hold
13%
Sell
0%

More NTRA News

Simply Wall St 6d
Is Natera’s CytoDyn ctDNA Tie-Up and Board Refresh Reframing the Investment Case for NTRA?

Natera, Inc. recently announced a collaboration with CytoDyn to use its Signatera assay and oncology real-world data to analyze circulating tumor DNA and molecu...

Is Natera’s CytoDyn ctDNA Tie-Up and Board Refresh Reframing the Investment Case for NTRA?
TipRanks 6d
Natera Shareholders Approve Equity Plan and Governance Proposals

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

People also own

Based on the portfolios of people who own NTRA. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.